These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
121 related articles for article (PubMed ID: 37390983)
1. Approved but Unavailable: A Mystery-Caller Survey of Mifepristone Access in a Large Ontario City. Guarna G; Kotait M; Blair R; Vu N; Yakoub D; Davis R; Costescu D J Obstet Gynaecol Can; 2023 Nov; 45(11):102178. PubMed ID: 37390983 [TBL] [Abstract][Full Text] [Related]
2. A Retrospective Cost-Effectiveness Analysis of Mifepristone-Misoprostol Medical Abortions in the First Year at the Regina General Hospital. Hunter C; Jensen J; Imeah B; McCarron M; Clark M J Obstet Gynaecol Can; 2021 Feb; 43(2):211-218. PubMed ID: 33153943 [TBL] [Abstract][Full Text] [Related]
3. Mifepristone-Misoprostol Use for Second- and Third-Trimester Medical Termination of Pregnancy in a Canadian Tertiary Care Centre. Vlad S; Boucoiran I; St-Pierre ÉR; Ferreira E J Obstet Gynaecol Can; 2022 Jun; 44(6):683-689. PubMed ID: 35114381 [TBL] [Abstract][Full Text] [Related]
4. Integrating mifepristone into primary care in Canada's capital: A multi-methods exploration of the Medical Abortion Access Project. LaRoche KJ; Wylie A; Persaud M; Foster AM Contraception; 2022 May; 109():37-42. PubMed ID: 35031301 [TBL] [Abstract][Full Text] [Related]
5. Pharmacist direct dispensing of mifepristone for medication abortion in Canada: a survey of community pharmacists. Zusman EZ; Munro S; Norman WV; Soon JA BMJ Open; 2022 Oct; 12(10):e063370. PubMed ID: 36207038 [TBL] [Abstract][Full Text] [Related]
6. Exploring Canadian women's knowledge of and interest in mifepristone: results from a national qualitative study with abortion patients. Vogel KI; LaRoche KJ; El-Haddad J; Chaumont A; Foster AM Contraception; 2016 Aug; 94(2):137-42. PubMed ID: 27125893 [TBL] [Abstract][Full Text] [Related]
7. Management of first-trimester miscarriage: a systematic review and network meta-analysis. H Al Wattar B; Murugesu N; Tobias A; Zamora J; Khan KS Hum Reprod Update; 2019 May; 25(3):362-374. PubMed ID: 30753490 [TBL] [Abstract][Full Text] [Related]
8. Medication abortion: Potential for improved patient access through pharmacies. Raifman S; Orlando M; Rafie S; Grossman D J Am Pharm Assoc (2003); 2018; 58(4):377-381. PubMed ID: 29752204 [TBL] [Abstract][Full Text] [Related]
9. Provision of menstrual regulation with medication among pharmacies in three municipal districts of Bangladesh: a situation analysis. Huda FA; Mahmood HR; Alam A; Ahmmed F; Karim F; Sarker BK; Al Haque N; Ahmed A Contraception; 2018 Feb; 97(2):144-151. PubMed ID: 29175274 [TBL] [Abstract][Full Text] [Related]
10. "I'll just deal with this on my own": a qualitative exploration of experiences with self-managed abortion in the United States. Raifman S; Ralph L; Biggs MA; Grossman D Reprod Health; 2021 May; 18(1):91. PubMed ID: 33947413 [TBL] [Abstract][Full Text] [Related]
11. Feasibility of assessing the safety and effectiveness of menstrual regulation medications purchased from pharmacies in Bangladesh: a prospective cohort study. Footman K; Scott R; Taleb F; Dijkerman S; Nuremowla S; Reiss K; Church K Contraception; 2018 Feb; 97(2):152-159. PubMed ID: 28823841 [TBL] [Abstract][Full Text] [Related]
12. Pharmacy workers in Nepal can provide the correct information about using mifepristone and misoprostol to women seeking medication to induce abortion. Tamang A; Puri M; Lama K; Shrestha P Reprod Health Matters; 2015 Feb; 22(44 Suppl 1):104-15. PubMed ID: 25702074 [TBL] [Abstract][Full Text] [Related]
13. Provision of first-trimester medication abortion in 2019: Results from the Canadian abortion provider survey. Ennis M; Renner R; Guilbert E; Norman WV; Pymar H; Kean L; Carson A; Martin-Misener R; Dunn S Contraception; 2022 Sep; 113():19-25. PubMed ID: 35351448 [TBL] [Abstract][Full Text] [Related]
14. Management of early pregnancy loss among obstetrician-gynecologists in Massachusetts and barriers to mifepristone use. Neill S; Hoe E; Fortin J; Goldberg AB; Janiak E Contraception; 2023 Oct; 126():110108. PubMed ID: 37394110 [TBL] [Abstract][Full Text] [Related]
15. "It gives you autonomy over your own choices": A qualitative study of Canadian abortion patients' experiences with mifepristone and misoprostol. LaRoche KJ; Foster AM Contraception; 2020 Jul; 102(1):61-65. PubMed ID: 32304768 [TBL] [Abstract][Full Text] [Related]
16. Comparison of Outcomes before and after Ohio's Law Mandating Use of the FDA-Approved Protocol for Medication Abortion: A Retrospective Cohort Study. Upadhyay UD; Johns NE; Combellick SL; Kohn JE; Keder LM; Roberts SC PLoS Med; 2016 Aug; 13(8):e1002110. PubMed ID: 27575488 [TBL] [Abstract][Full Text] [Related]
17. Advancing Reproductive Health through Policy-Engaged Research in Abortion Care. Munro SB; Dunn S; Guilbert ER; Norman WV Semin Reprod Med; 2022 Nov; 40(5-06):268-276. PubMed ID: 36746159 [TBL] [Abstract][Full Text] [Related]
18. Vaginal misoprostol administered 1, 2, or 3 days after mifepristone for early medical abortion: A randomized trial. Schaff EA; Fielding SL; Westhoff C; Ellertson C; Eisinger SH; Stadalius LS; Fuller L JAMA; 2000 Oct; 284(15):1948-53. PubMed ID: 11035891 [TBL] [Abstract][Full Text] [Related]
19. Trends in medication abortion provision before and after the introduction of mifepristone: A study of the National Abortion Federation's Canadian member services. Yalahow A; Doctoroff J; Mark A; Foster AM Contraception; 2020 Aug; 102(2):119-121. PubMed ID: 32325077 [TBL] [Abstract][Full Text] [Related]
20. Mifepristone by prescription: a dream in the United States but reality in Australia. Grossman D; Goldstone P Contraception; 2015 Sep; 92(3):186-9. PubMed ID: 26096369 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]